Belluscura Commences Premarket Launch of DISCOV-R™

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

Belluscura plc

("Belluscura" or the "Company" or "Group")

 Belluscura Commences Premarket Launch of the DISCOV-R™ portable oxygen concentrator

Innovative new product is expected to transform portable oxygen industry by being nearly 50% lighter than competitive products on the market.

LONDON, U.K. AND PLANO, TX, U.S. (29 June 2023). Belluscura plc (AIM:BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that it has commenced the premarket launch of its DISCOV-R portable oxygen concentrator (POC), including a patient usability study. 

Participants in the patient usability study have provided very positive feedback on the new device, including statements such as, "I cannot believe how light it is", "I prefer this over any other device available on the market", and "I would buy this right now if it were available."

The DISCOV-R weighs approximately 6.5 lbs while capable of producing two litres of continuous flow oxygen or, alternatively, delivering 8 pulse dose settings to meet the patient's supplemental oxygen needs. The Company's patented technology allows the DISCOV-R to produce nearly three times as much oxygen by weight as comparative dual flow concentrators. Such characteristics are expected to significantly increase the mobility of patients.

Simultaneously, the company continues to move forward with its CE and UKCA registration mark application for the X-PLOR POC in the EU and UK, respectively, by conducting a similar patient useability study. Finally, registration of the X-PLOR in the Peoples Republic of China is progressing after the recent registration of the Company's subsidiary, Shenzhen Belluscura Technology Company Limited.

Robert Rauker, Chief Executive Officer, Belluscura plc, commented:

"We are very pleased that the premarket launch of the DISCOV-R occurred in H1 as previously anticipated by the Company. We are further excited by the very positive feedback from the initial users in the study. The full commercial launch of the DISCOV-R is anticipated to occur in Q3 of this 2023, followed by a ramp up of production thereafter to meet the anticipated demand of the product."

For further information please contact:

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.